Skip to main content

Advertisement

Table 1 Demographic and clinical features of the sample

From: A biomarker study in long-lasting amnestic mild cognitive impairment

  Patient sample (n = 30)
Female/male ratio 12/18
Age in years (mean ± SD) 74.1 ± 4.8
Age range in years 65–84
Years of education (mean ± SD) 10.3 ± 4.5
Disease duration in months at first evaluation (mean ± SD) 44.5 ± 25.5
Months of follow-up (mean ± SD) 58.3 ± 10.1
Disease duration in months at follow-up (mean ± SD) 102.8 ± 28.1
MMSE adjusted score at first evaluation (mean ± SD) 26.5 ± 2.1
MMSE adjusted score at follow-up (mean ± SD) 25.1 ± 2.5
CDR Sum of Boxes at first evaluation (mean ± SD) 1.91 ± 0.6
CDR Sum of Boxes at follow-up (mean ± SD) 2.9 ± 1.7
Diagnosis at first evaluation 15 s-aMCI, 15 m-aMCI
Diagnosis at follow-up 9 s-aMCI, 21 m-aMCI
Lumbar puncture (no. of subjects) 20/30
 CSF Aβ42 and t-tau/p-tau normal values 7/20
 CSF Aβ42 low values 10/20
 CSF p-Tau/t-tau high values 3/20
Amyloid-PET (no. of subjects) 16/30
 SUVr values from 1.0 to 1.45 8/16
 SUVr values from 1.45 to 1.80 6/16
 SUVr values from 1.80 to 1.90 2/16
  1. Abbreviations: MMSE Mini Mental State Examination, CDR Clinical Dementia Rating, CSF Cerebrospinal fluid, 42  β-Amyloid (1–42) protein, t-tau Total tau, p-tau Phosphorylated tau, s-aMCI Single-domain amnestic mild cognitive impairment, m-aMCI Multiple-domain amnestic mild cognitive impairment, PET Positron emission tomography